There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Clovis Oncology (CLVS) and IMV (IMV) with bullish sentiments.
Clovis Oncology (CLVS)
In a report issued on December 29, Edward White from H.C. Wainwright maintained a Buy rating on Clovis Oncology, with a price target of $15.00. The company’s shares closed last Thursday at $4.98.
According to TipRanks.com, White is a top 100 analyst with an average return of 43.5% and a 57.6% success rate. White covers the Healthcare sector, focusing on stocks such as Spectrum Pharmaceuticals, Karyopharm Therapeutics, and Silverback Therapeutics.
Clovis Oncology has an analyst consensus of Hold, with a price target consensus of $7.67.
See today’s analyst top recommended stocks >>
IMV (IMV)
H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on IMV on December 28 and set a price target of $13.00. The company’s shares closed last Thursday at $3.46.
According to TipRanks.com, Pantginis is a top 100 analyst with an average return of 36.5% and a 64.8% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Catabasis Pharmaceuticals, and Lineage Cell Therapeutics.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for IMV with a $7.17 average price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
